L2Be Pharma
Turnover is estimated at about €150,000, probably between €87,000 and €260,000. The micro format does not state turnover.
Balance sheet
balance sheet total €153,570 on 31-12-2025in euro
in euro
Position in the sector
37.3%
Higher than 40% of the 4,579 companies filing micro accounts in other professional activities (NACE 74) in 2025.
1.59
Higher than 43% of the 4,394 companies filing micro accounts in other professional activities (NACE 74) in 2025.
9.8%
Higher than 50% of the 4,429 companies filing micro accounts in other professional activities (NACE 74) in 2025.
Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202110 months |
|---|---|---|---|---|---|---|
| - | 31,795 | 57,271 | 11,276 | 67,490 | ||
| - | 22,224 | 43,320 | 6,017 | 48,014 | ||
| - | 0 | 0 | 173 | 2,394 | ||
| 22,385 | 10,263 | 27,784 | 13,408 | - | ||
| 57,221 | 57,221 | 99,959 | 56,637 | 50,620 | ||
| 37.3% | 38.7% | 71.3% | 61.7% | 59.7% | ||
| 1.59 | 1.63 | 3.49 | 2.59 | 2.45 | ||
| 1.68 | 1.59 | 0.40 | 0.62 | 0.67 | ||
| 26.2% | 38.6% | 42.8% | 9.5% | 90.3% | ||
| 9.8% | 14.9% | 30.6% | 5.8% | 54.0% | ||
| - | 14.55 | 25.04 | 4.79 | 74.96 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 202110 months |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
153,570 | 147,948 | 140,340 | 92,741 | 86,700 | |
20 |
- | - | - | - | 173 | |
21/28 |
- | - | 161 | 584 | 1,007 | |
22/27 |
- | - | 161 | 584 | 1,007 | |
24 |
- | - | 161 | 584 | 1,007 | |
29/58 |
153,570 | 147,948 | 140,179 | 92,157 | 85,521 | |
40/41 |
28,622 | 33,432 | 40,262 | 29,231 | 31,605 | |
40 |
21,599 | 33,432 | 40,262 | 29,231 | 31,605 | |
41 |
7,023 | - | - | - | - | |
54/58 |
123,358 | 100,973 | 90,710 | 62,926 | 49,518 | |
490/1 |
1,590 | 13,544 | 9,207 | - | 4,398 | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
153,570 | 147,948 | 140,340 | 92,741 | 86,700 | |
10/15 |
57,221 | 57,221 | 100,117 | 57,221 | 51,799 | |
10/11 |
5,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
13 |
52,221 | 52,221 | 95,117 | 52,221 | 46,799 | |
133 |
52,221 | 52,221 | 95,117 | 52,221 | 46,799 | |
17/49 |
96,349 | 90,728 | 40,223 | 35,520 | 34,901 | |
42/48 |
96,349 | 90,728 | 40,220 | 35,520 | 34,901 | |
44 |
4,016 | 4,465 | 8,784 | 5,279 | 6,749 | |
440/4 |
4,016 | 4,465 | 8,784 | 5,279 | 6,749 | |
45 |
20,720 | 29,075 | 29,638 | 30,009 | 27,879 | |
450/3 |
17,420 | 25,775 | 26,338 | 26,709 | 24,879 | |
454/9 |
3,300 | 3,300 | 3,300 | 3,300 | 3,000 | |
47/48 |
71,614 | 57,188 | 1,798 | 233 | 272 | |
492/3 |
- | - | 3 | - | - | |
| Income statement | ||||||
9900 |
36,781 | 32,550 | 57,436 | 11,670 | 67,586 | |
630 |
- | 161 | 423 | 595 | 1,214 | |
640/8 |
15,439 | 754 | 165 | 395 | 96 | |
9901 |
21,342 | 31,634 | 56,848 | 10,680 | 66,275 | |
75/76B |
839 | - | 3 | 1 | - | |
75 |
839 | - | 3 | 1 | - | |
65/66B |
2,292 | 2,186 | 2,287 | 2,352 | 900 | |
65 |
2,292 | 2,186 | 2,287 | 2,352 | 900 | |
9903 |
19,889 | 29,448 | 54,564 | 8,329 | 65,375 | |
67/77 |
4,902 | 7,386 | 11,668 | 2,907 | 18,576 | |
9904 |
14,987 | 22,063 | 42,897 | 5,421 | 46,799 | |
9905 |
14,987 | 22,063 | 42,897 | 5,421 | 46,799 | |
| Appropriation of the result | ||||||
9906 |
14,987 | 22,063 | 42,897 | 5,421 | 46,799 | |
791/2 |
- | 42,897 | - | - | - | |
691/2 |
- | - | 42,897 | 5,421 | 46,799 | |
6921 |
- | - | 42,897 | 5,421 | 46,799 | |
794 |
- | 335 | - | - | - | |
694/7 |
14,987 | 65,294 | - | - | - | |
694 |
14,987 | 65,294 | - | - | - | |
| Document | ||||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 23-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 23-06-2026 | 2026-00186459 | |
| 31-12-2024 | micro format | 06-08-2025 | 2025-00366548 | |
| 31-12-2023 | micro format | 05-07-2024 | 2024-00220436 | |
| 31-12-2022 | micro format | 29-08-2023 | 2023-00376440 | |
| 31-12-2021 | micro format | 24-08-2022 | 2022-20315981 |
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | - | - | - | €2,394 |
| - | €161 | €423 | €595 | €1,214 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on L2Be Pharma
The operating result for 2025 is 33% lower than in 2024 and the lowest since 2022. It is the second fall in a row.
Debt's share of the balance-sheet total rises from 61.3% to 62.7%. Debt is higher.